Abstract
The purpose of this study was to prepare recombinant human epidermal growth factor (rhEGF) collagen sponges for topical applications and investigate the effects of different types of crosslinked collagen sponges as platforms for the controlled release of rhEGF. The microstructure and the drug release rates of collagen sponges were modified through treatment with different types (glutaraldehyde (GTA), genipin and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC)), different concentrations of crosslinking agents and various preparation conditions. A controlled release profile was observed for the crosslinked collagen sponges as compared to the non-crosslinked ones. The results indicated that the GTA crosslinked sponges have the most potent controlling effect. As the amount of GTA increased, a greater rigidity of the collagen sponge structure combined with a lower hydrophilicity was observed, leading to a decreased drug release rate and an increased water uptake. This study also demonstrated that a good correlation was obtained for in vitro release rates of rhEGF using the power model. The crosslinked rhEGF collagen sponges showed a successful delivery of rhEGF in bioactive form to stimulate cell proliferation.
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs10856-007-3249-5/MediaObjects/10856_2007_3249_Fig1_HTML.gif)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs10856-007-3249-5/MediaObjects/10856_2007_3249_Fig2_HTML.gif)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs10856-007-3249-5/MediaObjects/10856_2007_3249_Fig3_HTML.gif)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs10856-007-3249-5/MediaObjects/10856_2007_3249_Fig4_HTML.gif)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs10856-007-3249-5/MediaObjects/10856_2007_3249_Fig5_HTML.gif)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs10856-007-3249-5/MediaObjects/10856_2007_3249_Fig6_HTML.jpg)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs10856-007-3249-5/MediaObjects/10856_2007_3249_Fig7_HTML.gif)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs10856-007-3249-5/MediaObjects/10856_2007_3249_Fig8_HTML.gif)
Similar content being viewed by others
References
G. CARPENTER and S. COHEN, Ann. Rev. Biochem. 48 (1979) 193
I. K. COHEN, M. C. CROSSLAND, A. GARRETT and R. F. DIEGELMANN, Plast. Reconstr. Surg. 96 (1995) 251
J. M. BOWER, R. CAMBLE, H. GREGORY, E. L. GERRING and I. R. WILLSHIRE, Experientia 31 (1975) 825
G. L. BROWN, G. SCHULTZ, J. R. BRIGHTWELL and G. R. TOBIN, Surg. Forum. 35 (1984) 565
G. L. BROWN, L. CURTSINGER, J. R. BRIGHTWELL, D. M. ACKERMAN, G. R. TOBIN, H. C. POLK, C. GEORGE-NASCIMENTO, P. VALENZUELA and G. S. SCHULTZ, J. Exp. Med. 163 (1986) 1319
G. L. BROWN, L. B. NANNEY, J. GRIFFEN, A. B. CRAMER, J. M. YANCEY, I. L. CURTSINGER, L. HOLTZIN, G. S. SCHULTZ, M. J. JURKIEWICZ and J. B. LYNCH, N. Engl. J. Med. 321 (1989) 76
A. R. C. LEE, Y. SUZUKI, K. H. JUNG, J. NISHIGAKI, Y. HAMAI and A. SHIGEMATSU, Proc. Control. Release Soc. 23 (1996) 325
N. CELEBI, N. ERDEN, B. GONUL and M. KOZ, J. Pharm. Pharmacol. 46 (1994) 386
B. GONUL, T. SOYLEMEZOGLU, A. BABUL and N. CELEBI, J. Pharm. Pharmacol. 50 (1998) 641
M. LAATO, J. NIINIKOSKI, L. LEBEL and B. GERDIN, Ann. Surg. 203 (1986) 379
J. W. THORNTON, C. A. HESS, V. CASSINGHAM and R. H. BARTLETT, Burns. Incl. Therm. Inj. 8 (1982) 156
H. LI, J. H. SONG, J. S. PARK and K. HAN, Int. J. Pharm. 258 (2003) 11
V. FALANGA, W. H. EAGLSTEIN, B. BUCALO, M. H. KATZ, B. HARRIS and P. CARSON, J. Dermatol. Surg. Oncol. 18 (1992) 604
N. CELEBI, A. TURKYILMAZ, B. GONUL and C. OZOGUL, J. Control. Release. 83 (2002) 197
A. L. RUBIN, T. MIYATA and K. H. STENZEL, J. Macromol. Sci. Chem. 3 (1969) 113
M. CHVAPIL, R. L. KRONENTHAL and W. WINKLE, Connect. Tissue Res. 6 (1973) 1
M. MAEDA, K. KADOTA, M. KAJIHARA, A. SANO and K. FUJIOKA, J. Control. Release 77 (2001) 261
T. OKADA, T. HAYASHI and Y. IKADA, Biomaterials 13 (1992) 448
L. H. H. OLDEDAMINK, P. J. DIJKSTRA, J. A. VANLUYN, P. B. CANWACHEM, P. NIEUWENHUIS and J. FEIJEN, J. Mater. Sci. 6 (1995) 460
H. O. HO, C. W. LIN and M. T. SHEU, J. Control. Release 77 (2001) 97
M. T. SHEU, J. C. HUANG, G. C. YEH and H. O. HO, Biomaterials 22 (2001) 1713
W. A. BUBNIS and C. M. OFNER III, Anal. Biochem. 207 (1992) 129
X. H. WANG, D. P. LI, W. J. WANG, Q. L. FENG, F. Z. CUI, Y. X. XU, X. H. SONG and M. VAN DER WERF, Biomaterials 24 (2003) 3213
P. L. RITGER and N. S. PEPPAS, J. Control. Release 5 (1987) 37
Acknowledgments
This work was supported by a grant from the National Science Council of Taiwan, R.O.C. (NSC-94-2320-B-214-005). I am indebted to Prof. Yi-Hung Tsai (Kaohsiung Medical University, Taiwan) for his encouragement.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yang, CH. Evaluation of the release rate of bioactive recombinant human epidermal growth factor from crosslinking collagen sponges. J Mater Sci: Mater Med 19, 1433–1440 (2008). https://doi.org/10.1007/s10856-007-3249-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10856-007-3249-5